-
公开(公告)号：US20240124427A1
公开(公告)日：2024-04-18
申请号：US18264751
申请日：2022-02-08
发明人： Martin BOLLI , John GATFIELD , Corinna GRISOSTOMI , Lubos REMEN , Christoph SAGER , Cornelia ZUMBRUNN
IPC分类号： C07D405/14
CPC分类号： C07D405/14
摘要： The present invention relates to compounds of Formula (I)
wherein X, Ar1, Ar2, L, n, m, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.-
公开(公告)号：US20230303486A1
公开(公告)日：2023-09-28
申请号：US18003226
申请日：2021-06-24
发明人： Olivier BEZENCON , Caroline DEYMIER , Jens-Uwe PETERS , Romain SIEGRIST , Jean-Philippe SURIVET
IPC分类号： C07C275/26 , C07D213/40 , C07D239/26 , A61P25/08
CPC分类号： C07C275/26 , A61P25/08 , C07D213/40 , C07D239/26 , C07C2601/04
摘要： The invention relates to compounds of Formula (I)
wherein X1, X2, X3, L, RX4, R1, R2A, R2B, R3, R4, R5, and R6 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing one or more compounds of Formula (I), and to the use of such compounds as medicaments, especially as Kv7 openers.-
公开(公告)号：US20230295182A1
公开(公告)日：2023-09-21
申请号：US18248007
申请日：2021-10-05
发明人： Martin BOLLLI , John GATFIELD , Corinna GRISOSTOMI , Lubos REMEN , Christoph SAGER , Cornelia ZUMBRUNN
IPC分类号： C07D498/10 , C07D413/14
CPC分类号： C07D498/10 , C07D413/14
摘要： The present invention relates to compounds of Formula (I)
wherein Ar1, A, B, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.-
公开(公告)号：US11739070B2
公开(公告)日：2023-08-29
申请号：US16963101
申请日：2019-01-18
发明人： Sylvie Froidevaux , Francis Hubler , Mark Murphy , Dorte Renneberg , Simon Stamm
IPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D471/04
CPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D471/04
摘要： The present invention relates to derivatives of formula (I)
wherein ring A, X, Y, Z, R1, R2, R3 and R4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as C5a receptor modulators.-
公开(公告)号：US11713297B2
公开(公告)日：2023-08-01
申请号：US17479341
申请日：2021-09-20
发明人： Vitor Oliveira , Ivan Pogorelic , Jean-Paul Roduit
IPC分类号： A61K9/48 , C07D211/40
CPC分类号： C07D211/40 , A61K9/4858 , C07B2200/13
摘要： The invention relates to a crystalline form of [(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)-piperidine-3,4,5-triol, processes for the preparation thereof, pharmaceutical compositions containing such a crystalline form, and its use as a medicament, especially as glycolipid biosynthesis inhibitor.
-
公开(公告)号：US20230174514A1
公开(公告)日：2023-06-08
申请号：US17997531
申请日：2021-04-30
发明人： Oliver ALLEMANN , Eva CAROFF , Alexia CHAVANTON-ARPEL , Andrew CROXFORD , Francis HUBLER , Loïc JACOB , Emmanuel MEYER , Sylvia RICHARD-BILDSTEIN
IPC分类号： C07D401/14 , C07D401/12 , C07D405/14 , C07D417/14 , C07D413/14
CPC分类号： C07D401/14 , C07D401/12 , C07D405/14 , C07D417/14 , C07D413/14
摘要： The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders.
-
公开(公告)号：US20230136562A1
公开(公告)日：2023-05-04
申请号：US17997483
申请日：2021-04-27
发明人： Olivier BEZENCON , Caroline DEYMIER , Jens-Uwe PETERS , Romain SIEGRIST , Jean-Philippe SURIVET
IPC分类号： C07C275/26 , C07D213/16 , C07D217/26 , C07D239/26 , C07D257/04 , C07D255/02 , C07C317/28
摘要： The invention relates to compounds of Formula (I) wherein X1, X2, X3, Y, R1, R2A, R2B, R3, and R4 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing one or more compounds of Formula (I), and to the use of such compounds as medicaments, especially as Kv7 openers.
-
公开(公告)号：US20230134935A1
公开(公告)日：2023-05-04
申请号：US17996499
申请日：2021-04-16
IPC分类号： A61K31/4192 , A61P25/20 , A61K9/28
摘要： The invention relates to daridorexant: Formula (I) or drochloric acid salt; for use in a method of treatment of sleep disorders such as especially insomnias, wherein daridorexant improves daytime performance, especially reduces daytime sleepiness associated to such sleep disorder
-
公开(公告)号：US20220175775A1
公开(公告)日：2022-06-09
申请号：US17549828
申请日：2021-12-13
发明人： Heinz FRETZ , Isabelle LYOTHIER , Julien POTHIER , Sylvia RICHARD-BILDSTEIN , Thierry SIFFERLEN , Lorenza WYDER PETERS , Davide POZZI , Olivier CORMINBOEUF
IPC分类号： A61K31/506 , A61P35/00 , A61K45/06 , C07D403/12 , C07D403/14 , C07D413/14 , C07D417/14
摘要： The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
-
公开(公告)号：US11325899B2
公开(公告)日：2022-05-10
申请号：US16614211
申请日：2018-05-17
发明人： Christoph Boss , Olivier Corminboeuf , Heinz Fretz , Isabelle Lyothier , Davide Pozzi , Sylvia Richard-Bildstein , Hervé Siendt , Thierry Sifferlen
IPC分类号： C07D409/14 , C07D405/12 , C07D413/14
摘要： The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
-
-
-
-
-
-
-
-
-
搜索结果
119 条记录 (耗时 0.03 秒)
